Serial Number:
87323906
Mark:
TANVEX
Status:
Registered
Status Date:
05-25-2021
Filing Date:
Registration Number:
6358665
Registration Date:
05-25-2021
Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; medicinal agent for human use, namely, medicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; haematogen, namely, blood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis
Mark Description:
The mark consists of the word "TANVEX" in the color light blue in stylized typeface.
Class:
Pharmaceutical and veterinary preparations
Type of Mark:
Trademark
Published for Opposition Date:
03-09-2021
Owner:
Mark Drawing Status:
Words, Letters, and/or Numbers in Stylized From
Abandon Date:
N/A
Business Name:
BAKER & MCKENZIE LLP
Correspondent Name: